CardiovascularResearch Phase

Apelin-13

Intravenous

Overview

Apelin-13 is a 13-amino acid endogenous peptide that represents the most potent and abundant isoform of the apelin family. It acts as the ligand for the APJ receptor (also known as the apelin receptor), a G protein-coupled receptor expressed in vascular endothelium, cardiomyocytes, and other tissues.

Mechanism of Action

The peptide induces vasodilation, enhances cardiac contractility, and modulates fluid homeostasis, providing therapeutic rationale for heart failure and pulmonary hypertension. Its structure consists of a highly conserved C-terminal sequence critical for receptor binding and biological activity..

Research Summary & Key Findings

Preclinical studies in rodent models have demonstrated improved cardiac output, reduced afterload, and attenuated pathological remodeling following apelin-13 administration. Clinical translation has been limited, with small exploratory human studies suggesting hemodynamic benefits in heart failure patients, but no large-scale randomized controlled trials have been completed to date. Further investigation is needed to establish safety and efficacy profiles for clinical use.

Clinical Status

Research Phase

Apelin-13 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intravenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Apelin-13 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Apelin-13.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.